• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IFN gamma protein

Activity

0.02-0.14 ng/mL EC50

Specific Activity

>1.00 x 107 IU/mg

Species Reactivity

human,mouse,pig,rat

Purity

>95%

Cat no : HZ-1301

Synonyms

IFG, IFI, IFN gamma, IFNG, Immune interferon, Interferon gamma, interferon, gamma

Validation Data Gallery

  • Purity of recombinant human IFN gamma was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

    Purity of recombinant human IFN gamma was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

  • Recombinant human IFN gamma (HZ-1301) dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

    Recombinant human IFN gamma (HZ-1301) dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

  • Proteintech IFN gamma (HZ-1301) demonstrates a 3-fold lower EC50 and equivalent dose-dependent inhibition of proliferation to a leading competitor. Recombinant human IFN gamma dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

    Proteintech IFN gamma (HZ-1301) demonstrates a 3-fold lower EC50 and equivalent dose-dependent inhibition of proliferation to a leading competitor. Recombinant human IFN gamma dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

Technical Specifications

GeneID 3458
Species Human
Expression HEK293
Activity 0.02-0.14 ng/mL EC50
Specific Activity>1.00 x 107 IU/mg
Purity >95%
Endotoxin<1 EU/μg
Accession NumberP01579
Molecular Mass 17 and 21 to 32 kDa reduced and non-reduced, homodimer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human,mouse,pig,rat

Stability and Reconstitution

Stability and Storage Lyophilized proteins are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human albumin (HSA).

Background

Interferon gamma (IFN γ), is a type II interferon that provides immunity against bacterial, viral and protozoan infections. In its active form, IFN γ is a glycosylated, non-covalently linked homodimer of 17, 21-32 kDa subunits. It is produced by a number of immune cell types including natural killer cells, natural killer T cells, and effector lymphocyte T cells following antigenic and inflammatory triggers. The IFN γ dimer binds to its cognate receptor which has two subunits: IFN-γR1 which is the ligand-binding chain (α chain) and IFN-γR2, the signal-transducing chain (β chain). Binding to the receptor activates the JAK/STAT pathway which in turn activates IFN γ responsive genes. While IFN γ can inhibit viral replication, it also works as an immune-modulator and immune-stimulator by increasing surface expression of class I MHC proteins (PMID: 19268625; 10688427)

Synonyms

IFG, IFI, IFN gamma, IFNG, Immune interferon, Interferon gamma, interferon, gamma

Publications

SpeciesTitle
mouse

Mol Cell

Serine synthesis sustains macrophage IL-1β production via NAD+-dependent protein acetylation

Authors - Chuanlong Wang
View Article
mouse

EMBO Mol Med

Glutathione peroxidase 8 negatively regulates caspase-4/11 to protect against colitis.

Authors - Jye-Lin Hsu
View Article
human

Virulence

The lipoprotein NlpD in Cronobacter sakazakii responds to acid stress and regulates macrophage resistance and virulence by maintaining membrane integrity.

Authors - Xuemeng Ji
View Article
human

Mol Neurobiol

Teriflunomide Promotes Blood-Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis

Authors - Yipeng Zhao
View Article
human

Cancer Sci

CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.

Authors - Xiaoge Niu
View Article
human

Clin Immunol

Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors - David AHorwitz
View Article